ReviewCurrent rheumatology reports2007
Malignancy and rheumatoid arthritis.
Review in Current rheumatology reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis.Arthritis research & therapy · 2008Pooled it
- Spondyloarthritis and Risk of Malignancy: A Narrative Review on a Still Controversial Issue.Rheumatology and therapy · 2025Review
- How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits.Current rheumatology reports · 2023Review
- The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus.Journal of clinical medicine · 2021Review
- Identification of the Main Active Components and Mechanism of Wang Bi Tablet in Treating Rheumatoid Arthritis Based on Integrative Pharmacology.Frontiers in pharmacology · 2021Article
- Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders.World journal of gastrointestinal pathophysiology · 2015Review
- Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting.PloS one · 2014Article
- [Gastrointestinal tumors. Clinical manifestations of paraneoplastic rheumatic symptoms].Zeitschrift fur Rheumatologie · 2011Review
- Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?Current rheumatology reports · 2011Review
- Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study.Rheumatology international · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The occurrence of cancer is not an infrequent event in patients with rheumatoid arthritis (RA). Indeed, following diagnosis of RA at a typical age (55 years), one in five patients will be diagnosed with cancer. In the vast majority of such cases, the cancer has nothing to do with RA or its treatment; rather, it represents the "background" risk applicable to all humans. In some cases, the cancer occurs as a result of factors also associated with the risk of developing RA (eg, smoking), even though no direct link exists between the cancer and the RA. In a fraction of cases, however, the cancer is causally associated with the RA disease or its treatments. This review summarizes our current understanding of the occurrence of cancer in RA, possible links to RA disease and to traditional and newer RA treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.